Literature DB >> 30301767

Three structurally and functionally distinct β-glucuronidases from the human gut microbe Bacteroides uniformis.

Samuel J Pellock1, William G Walton1, Kristen A Biernat1, Dariana Torres-Rivera1, Benjamin C Creekmore1, Yongmei Xu2, Jian Liu2, Ashutosh Tripathy3, Lance J Stewart4, Matthew R Redinbo5,3,6.   

Abstract

The glycoside hydrolases encoded by the human gut microbiome play an integral role in processing a variety of exogenous and endogenous glycoconjugates. Here we present three structurally and functionally distinct β-glucuronidase (GUS) glycoside hydrolases from a single human gut commensal microbe, Bacteroides uniformis We show using nine crystal structures, biochemical, and biophysical data that whereas these three proteins share similar overall folds, they exhibit different structural features that create three structurally and functionally unique enzyme active sites. Notably, quaternary structure plays an important role in creating distinct active site features that are hard to predict via structural modeling methods. The enzymes display differential processing capabilities toward glucuronic acid-containing polysaccharides and SN-38-glucuronide, a metabolite of the cancer drug irinotecan. We also demonstrate that GUS-specific and nonselective inhibitors exhibit varying potencies toward each enzyme. Together, these data highlight the diversity of GUS enzymes within a single Bacteroides gut commensal and advance our understanding of how structural details impact the specific roles microbial enzymes play in processing drug-glucuronide and glycan substrates.
© 2018 Pellock et al.

Entities:  

Keywords:  GI tract; bacteroides; carbohydrate metabolism; crystallography; drug reactivation; enzyme structure; glucuronidase; glycoside hydrolase; microbiome; structure-function

Mesh:

Substances:

Year:  2018        PMID: 30301767      PMCID: PMC6290157          DOI: 10.1074/jbc.RA118.005414

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  SignalP 4.0: discriminating signal peptides from transmembrane regions.

Authors:  Thomas Nordahl Petersen; Søren Brunak; Gunnar von Heijne; Henrik Nielsen
Journal:  Nat Methods       Date:  2011-09-29       Impact factor: 28.547

2.  Glycan foraging in vivo by an intestine-adapted bacterial symbiont.

Authors:  Justin L Sonnenburg; Jian Xu; Douglas D Leip; Chien-Huan Chen; Benjamin P Westover; Jeremy Weatherford; Jeremy D Buhler; Jeffrey I Gordon
Journal:  Science       Date:  2005-03-25       Impact factor: 47.728

3.  Protein homology model refinement by large-scale energy optimization.

Authors:  Hahnbeom Park; Sergey Ovchinnikov; David E Kim; Frank DiMaio; David Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-05       Impact factor: 11.205

Review 4.  Glucuronides in the gut: Sugar-driven symbioses between microbe and host.

Authors:  Samuel J Pellock; Matthew R Redinbo
Journal:  J Biol Chem       Date:  2017-04-07       Impact factor: 5.157

5.  Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43.

Authors:  Kendle M Maslowski; Angelica T Vieira; Aylwin Ng; Jan Kranich; Frederic Sierro; Di Yu; Heidi C Schilter; Michael S Rolph; Fabienne Mackay; David Artis; Ramnik J Xavier; Mauro M Teixeira; Charles R Mackay
Journal:  Nature       Date:  2009-10-29       Impact factor: 49.962

6.  Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41.

Authors:  Buck S Samuel; Abdullah Shaito; Toshiyuki Motoike; Federico E Rey; Fredrik Backhed; Jill K Manchester; Robert E Hammer; S Clay Williams; Jan Crowley; Masashi Yanagisawa; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-17       Impact factor: 11.205

Review 7.  Understanding and modulating mammalian-microbial communication for improved human health.

Authors:  Sridhar Mani; Urs A Boelsterli; Matthew R Redinbo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-23       Impact factor: 13.820

8.  Protein structure prediction using Rosetta in CASP12.

Authors:  Sergey Ovchinnikov; Hahnbeom Park; David E Kim; Frank DiMaio; David Baker
Journal:  Proteins       Date:  2017-10-08

9.  An Atlas of β-Glucuronidases in the Human Intestinal Microbiome.

Authors:  Rebecca M Pollet; Emma H D'Agostino; William G Walton; Yongmei Xu; Michael S Little; Kristen A Biernat; Samuel J Pellock; Loraine M Patterson; Benjamin C Creekmore; Hanna N Isenberg; Rohini R Bahethi; Aadra P Bhatt; Jian Liu; Raad Z Gharaibeh; Matthew R Redinbo
Journal:  Structure       Date:  2017-06-01       Impact factor: 5.006

10.  Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.

Authors:  Bret D Wallace; Adam B Roberts; Rebecca M Pollet; James D Ingle; Kristen A Biernat; Samuel J Pellock; Madhu Kumar Venkatesh; Leah Guthrie; Sara K O'Neal; Sara J Robinson; Makani Dollinger; Esteban Figueroa; Sarah R McShane; Rachel D Cohen; Jian Jin; Stephen V Frye; William C Zamboni; Charles Pepe-Ranney; Sridhar Mani; Libusha Kelly; Matthew R Redinbo
Journal:  Chem Biol       Date:  2015-09-10
View more
  17 in total

1.  Discovering the Microbial Enzymes Driving Drug Toxicity with Activity-Based Protein Profiling.

Authors:  Parth B Jariwala; Samuel J Pellock; Dennis Goldfarb; Erica W Cloer; Marta Artola; Joshua B Simpson; Aadra P Bhatt; William G Walton; Lee R Roberts; Michael B Major; Gideon J Davies; Herman S Overkleeft; Matthew R Redinbo
Journal:  ACS Chem Biol       Date:  2019-12-12       Impact factor: 5.100

2.  Discovery and Characterization of FMN-Binding β-Glucuronidases in the Human Gut Microbiome.

Authors:  Samuel J Pellock; William G Walton; Samantha M Ervin; Dariana Torres-Rivera; Benjamin C Creekmore; Grace Bergan; Zachary D Dunn; Bo Li; Ashutosh Tripathy; Matthew R Redinbo
Journal:  J Mol Biol       Date:  2019-01-15       Impact factor: 5.469

3.  Functional metagenomic screening identifies an unexpected β-glucuronidase.

Authors:  Stefanie Neun; Paul Brear; Eleanor Campbell; Theodora Tryfona; Kamel El Omari; Armin Wagner; Paul Dupree; Marko Hyvönen; Florian Hollfelder
Journal:  Nat Chem Biol       Date:  2022-07-07       Impact factor: 16.174

4.  Characterizing the metabolic effects of the selective inhibition of gut microbial β-glucuronidases in mice.

Authors:  Marine P M Letertre; Aadra P Bhatt; Michael Harvey; Jeremy K Nicholson; Ian D Wilson; Matthew R Redinbo; Jonathan R Swann
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

5.  Structural and Biochemical Basis of a Marine Bacterial Glycoside Hydrolase Family 2 β-Glycosidase with Broad Substrate Specificity.

Authors:  Jian Yang; Shubo Li; Yu Liu; Ru Li; Lijuan Long
Journal:  Appl Environ Microbiol       Date:  2021-11-24       Impact factor: 5.005

6.  Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats.

Authors:  Chao Luo; Xu Wang; Han-Xue Huang; Xiao-Yuan Mao; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Psychopharmacology (Berl)       Date:  2020-10-23       Impact factor: 4.530

7.  Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens.

Authors:  Samantha M Ervin; Hao Li; Lauren Lim; Lee R Roberts; Xue Liang; Sridhar Mani; Matthew R Redinbo
Journal:  J Biol Chem       Date:  2019-10-21       Impact factor: 5.486

8.  Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity.

Authors:  Michael R Taylor; Kyle L Flannigan; Hannah Rahim; Amina Mohamud; Ian A Lewis; Simon A Hirota; Steven C Greenway
Journal:  Sci Adv       Date:  2019-08-07       Impact factor: 14.136

9.  Targeting Regorafenib-Induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases.

Authors:  Samantha M Ervin; Ronan P Hanley; Lauren Lim; William G Walton; Kenneth H Pearce; Aadra P Bhatt; Lindsey I James; Matthew R Redinbo
Journal:  ACS Chem Biol       Date:  2019-11-12       Impact factor: 4.634

10.  Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy.

Authors:  Aadra P Bhatt; Samuel J Pellock; Kristen A Biernat; William G Walton; Bret D Wallace; Benjamin C Creekmore; Marine M Letertre; Jonathan R Swann; Ian D Wilson; Jose R Roques; David B Darr; Sean T Bailey; Stephanie A Montgomery; Jeffrey M Roach; M Andrea Azcarate-Peril; R Balfour Sartor; Raad Z Gharaibeh; Scott J Bultman; Matthew R Redinbo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.